trending Market Intelligence /marketintelligence/en/news-insights/trending/qWUkhQmdeGCvNr70c5ygCw2 content esgSubNav
In This List

Delcath Systems updates reverse stock split ratio to 1-for-700

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Delcath Systems updates reverse stock split ratio to 1-for-700

Delcath Systems Inc. has increased the size of its reverse stock split to a ratio of 1-for-700.

The split will cut the New York-based company's estimated 1.4 billion issued and outstanding shares of common stock down to approximately 2.1 million. The move will take effect Dec. 24 and is larger than the company's previous ratio of 1-for-100.

American Stock Transfer & Trust Co. LLC is acting as the exchange agent and transfer agent for the reverse stock split.

Delcath Systems treats primary and metastatic liver cancers. Its investigational products include melphalan hydrochloride for injection, which is used to administer high-dose chemotherapy to the liver.